Tests of the new CaTeVac cancer vaccine have been completed in Russia and it is planned to start using the homemade dendritic cell vaccine in patients with soft tissue sarcomas in 2027. Documents are now being prepared to obtain approval for the production and clinical use of the drug. Development of the National Oncology Medical Research Center named after N. N. Petrov is supposed to help the immune system identify and destroy tumor cells. In the future, the vaccine could also be used to treat melanoma, kidney cancer and tumors of the central nervous system.

Tests of the new CaTeVac cancer vaccine have been completed in Russia and it is planned to start using the homemade dendritic cell vaccine in patients with soft tissue sarcomas in 2027. Documents are now being prepared to obtain approval for the production and clinical use of the drug. Development of the National Oncology Medical Research Center named after N. N. Petrov is supposed to help the immune system identify and destroy tumor cells. In the future, the vaccine could also be used to treat melanoma, kidney cancer and tumors of the central nervous system.